USPTO Examiner NOBLE MARCIA STEPHENS - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18662102MODULAR GENETICALLY ENGINEERED CELL AND METHODS OF GENERATION THEREOFMay 2024August 2025Allow1511YesNo
18524967GENE THERAPY FOR AADC DEFICIENCYNovember 2023June 2025Allow1910NoNo
18518212ABCA4 TRANS-SPLICING MOLECULESNovember 2023June 2025Allow1932YesNo
18490841METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEMOctober 2023February 2026Allow2820NoNo
18486682Recombinant Adeno-Associated Vectors For Targeted TreatmentOctober 2023August 2025Abandon2210NoNo
18223338MODIFIED NK-92 haNK003 CELLS FOR THE CLINICJuly 2023August 2025Allow2520YesNo
18332621METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2023April 2025Allow2210NoNo
18332620METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2023March 2025Allow2210NoNo
18196192THYROID MANUFACTURING PROCESS AND SPECIFICATIONSMay 2023March 2026Allow3410NoNo
18300693Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use ThereofApril 2023May 2025Allow2510NoNo
18188421METHODS FOR REPROGRAMMING CELLS AND USES THEREOFMarch 2023October 2025Allow3120NoNo
18012894PYRUVATE KINASE DEFICIENCY (PKD) GENE EDITING TREATMENT METHODDecember 2022February 2026Allow3810NoNo
18068056GENE-EDITED NATURAL KILLER CELLSDecember 2022March 2025Allow2710YesNo
18074781NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITSDecember 2022December 2025Allow3610NoNo
18058457ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOFNovember 2022June 2025Allow3020YesNo
18057912Methods for monitoring physiological status of a body organNovember 2022December 2025Allow3621NoNo
17971677MEDIA FOR CULTURING STEM CELLSOctober 2022May 2025Allow3110YesNo
18047673TRANSGENIC MICEOctober 2022May 2025Abandon3001NoNo
17958816METHODS AND PRODUCTS FOR TRANSFECTIONOctober 2022July 2024Allow2210NoNo
17957598THERAPY FOR POLYGLUTAMINE (POLYQ) DISEASESSeptember 2022March 2024Allow1710NoNo
17916308DUAL AAV-MYO7A VECTORS WITH IMPROVED SAFETY FOR THE TREATMENT OF USH1BSeptember 2022March 2025Allow3031YesNo
17947846MICROFLUIDIC DEVICE, SYSTEM AND METHODS THEREOF FOR MEASURING AND RECORDING ELECTRICAL SIGNALS FROM A POOL OF MULTIPLE NEMATODESSeptember 2022March 2025Abandon3001NoNo
17823897RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEAugust 2022August 2023Allow1101YesNo
17898360METHODS FOR REPROGRAMMING SOMATIC CELLSAugust 2022March 2023Allow710NoNo
17821298METHODS AND PRODUCTS FOR TRANSFECTING CELLSAugust 2022November 2024Abandon2710YesNo
17819539ONE-STEP METHOD FOR PRODUCING ADENOVIRAL VECTORSAugust 2022March 2026Allow4320NoNo
17817966METHODS AND PRODUCTS FOR TRANSFECTING CELLSAugust 2022August 2024Allow2410NoNo
17816367Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseJuly 2022February 2026Abandon4311NoNo
17796064GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDERJuly 2022January 2026Allow4210NoNo
17793150MODULATING TLR/NF-KB AND P53 SIGNALING PATHWAYS TO ENHANCE INTERSPECIES CHIMERISM BETWEEN EVOLUTIONARYILY DISTANT SPECIESJuly 2022March 2026Allow4421NoNo
17805825DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODSJune 2022August 2024Abandon2710NoNo
17750705COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCYMay 2022April 2025Abandon3401NoNo
17741666LACTAM-MODIFIED ADENO-ASSOCIATED VIRUS VECTORSMay 2022October 2025Allow4111YesNo
17776100METHOD FOR DIRECT TRANSDIFFERENTIATION OF SOMATIC CELLMay 2022December 2025Allow4311YesNo
17775016GENERATION OF ENGINEERED REGULATORY T CELLSMay 2022November 2025Abandon4201NoNo
17732901Adeno-Associated Virus Virions for Treatment of EpilepsyApril 2022November 2024Allow3120NoNo
17730099ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANSApril 2022September 2024Abandon2941YesNo
17712785METHODS OF DIFFERENTIATING STEM CELL-DERIVED ECTODERMAL LINEAGE PRECURSORSApril 2022December 2023Allow2010NoNo
17703762NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTIONMarch 2022November 2024Abandon3241YesNo
17638905BIODEGRADABLE SOFT ELASTOMERS FOR REGENERATIVE ENGINEERINGFebruary 2022February 2026Allow4711NoNo
17678934TARGETED DISRUPTION OF THE MHC CELL RECEPTORFebruary 2022February 2026Abandon4701NoNo
17559314METHOD OF NOCICEPTOR DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS AND USES THEREOFDecember 2021September 2024Abandon3301NoNo
17553697RETROVIRAL VECTOR HAVING IMMUNE-STIMULATING ACTIVITYDecember 2021August 2024Abandon3210NoNo
17619165NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMSDecember 2021October 2025Abandon4701NoNo
17538699GENE-EDITED NATURAL KILLER CELLSNovember 2021September 2022Allow1011YesNo
17610661GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCERNovember 2021October 2025Abandon4701NoNo
17502421NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLSOctober 2021March 2022Allow510YesNo
17502479PHARMACEUTICAL COMPOSITIONS COMPRISING GENE-CORRECTED PRIMARY CELLSOctober 2021December 2022Allow1421YesNo
17502402NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED METHODS OF TREATMENTOctober 2021February 2023Abandon1621NoNo
17495087METHOD FOR DEVELOPING ORGAN THAT LACKS SPECIFIC FUNCTIONAL CELLOctober 2021April 2025Abandon4221YesNo
17449015OVARIAN FOLLICLE CELLS AND CONSTRUCTS FOR FERTILITY TREATMENT AND HORMONE REPLACEMENT THERAPYSeptember 2021November 2025Allow5021NoNo
17469441CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTIONSeptember 2021August 2023Allow2310NoNo
17463690Process of Using a Fish Plasma Component in a Nutrient Medium for Cell CultureSeptember 2021December 2022Abandon1521NoNo
17458609Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell TypesAugust 2021June 2024Allow3321YesNo
17433577AUGMENTATIONS TO LENTIVIRAL VECTORS (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) TO INCREASE EXPRESSIONAugust 2021January 2026Allow5321NoNo
17407718AAV-IDUA VECTOR FOR TREATMENT OF MPS I-ASSOCIATED BLINDNESSAugust 2021September 2024Allow3721NoNo
17402543PORCINE THY1 GENE PROMOTER SPECIFICALLY EXPRESSED IN NEURONSAugust 2021July 2023Allow2310NoNo
17383019METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLSJuly 2021June 2024Allow3520YesNo
17425043CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOFJuly 2021April 2025Allow4511NoNo
17422596ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANSJuly 2021November 2025Abandon5221NoNo
17363546COMPOSITIONS, SYSTEMS, AND METHODS FOR BASE DIVERSIFICATIONJune 2021May 2024Allow3511NoNo
17417829ANTHELMINTIC LABORATORY ANIMAL MODEL FOR HEARTWORMJune 2021March 2025Abandon4521YesNo
17348907NON-HUMAN ANIMALS MODELS OF RETINOSCHISISJune 2021May 2024Allow3520YesNo
17320676INDUCTION OF PLURIPOTENT CELLSMay 2021August 2024Allow3911NoNo
17288379MODIFIED CAS9 PROTEIN, AND USE THEREOFApril 2021February 2025Abandon4601NoNo
17285430METHOD OF OVEREXPRESSING TARGET GENE USING ELECTROMAGNETIC WAVE-REACTIVE PROMOTERApril 2021August 2025Allow5221YesNo
17282097GENETICALLY MODIFIED SALMON WHICH PRODUCE STERILE OFFSPRINGApril 2021August 2024Abandon4101NoNo
17208477CRISPR-BASED GENOME MODIFICATION AND REGULATIONMarch 2021November 2024Abandon4410NoNo
17276090COMPOSITION FOR INDUCING DEATH OF CELLS HAVING MUTATED GENE, AND METHOD FOR INDUCING DEATH OF CELLS HAVING MUTATED GENE BY USING COMPOSITIONMarch 2021February 2026Abandon5921NoNo
17198505USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLSMarch 2021January 2022Allow1130YesNo
17186877METHOD FOR PRODUCING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLSFebruary 2021March 2025Allow4931YesNo
17180585ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOFFebruary 2021February 2022Allow1221YesNo
17157745GENE THERAPY FOR AADC DEFICIENCYJanuary 2021August 2023Allow3120YesNo
17146200ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOFJanuary 2021September 2024Allow4421NoNo
17125449FRATAXIN EXPRESSION CONSTRUCTSDecember 2020January 2024Allow3720NoNo
17253518METHOD OF DIFFERENTIATING PRIMORDIAL GERM CELL INTO PRIMORDIAL FOLLICLE IN VITRODecember 2020March 2024Allow3920YesNo
17118981HUMANIZED HEART MUSCLEDecember 2020February 2025Abandon5021NoNo
17118064NON-MEIOTIC ALLELE INTROGRESSIONDecember 2020January 2024Abandon3811NoNo
16952807HUMANIZED SKELETAL MUSCLENovember 2020May 2024Allow4220NoNo
17091203Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain InjuriesNovember 2020August 2024Abandon4521NoNo
17086072METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTUREOctober 2020June 2023Allow3110YesNo
17065541Method For Differentiating Pluripotent Stem Cells Into Desired Cell TypeOctober 2020September 2023Allow3610NoNo
17039006CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCSSeptember 2020May 2025Allow5641YesNo
17034009METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMALSeptember 2020October 2025Allow6041NoNo
17040818Gene Editing for Autosomal Dominant DiseasesSeptember 2020May 2025Abandon5511NoNo
17019126SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIESSeptember 2020September 2025Abandon6021NoNo
16937370MODIFIED NK-92 haNK003 CELLS FOR THE CLINICJuly 2020April 2023Allow3310YesNo
16925518IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLSJuly 2020November 2023Allow4011NoNo
16913306METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2020May 2023Allow3410NoNo
16913315METHODS AND PRODUCTS FOR TRANSFECTING CELLSJune 2020May 2023Allow3510NoNo
16902368METHODS FOR PRODUCING HEPATOCYTESJune 2020March 2023Allow3310NoNo
16895732EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCERJune 2020July 2023Abandon3710NoNo
16890697PHARMACEUTICAL COMPOSITION COMPRISING AIMP2-DX2 FOR PREVENTING OR TREATING NEURONAL DISEASES AND USE THEREOFJune 2020June 2024Allow4930YesNo
16869394STEM CELL COMPOSITIONS FOR COSMETIC AND DERMATOLOGIC USEMay 2020May 2023Abandon3610NoNo
16869232METHODS AND PRODUCTS FOR TRANSFECTING CELLSMay 2020February 2021Allow1010YesNo
16864774ADIPONECTIN-EXPRESSING REGULATORY T-CELL PRECURSORS, COMPOSITION AND METHODS THEREOFMay 2020February 2026Abandon6051YesNo
16857894METHODS AND PRODUCTS FOR TRANSFECTING CELLSApril 2020September 2020Allow510NoNo
16757811COMPOSITIONS AND METHODS USEFUL IN REGENERATIVE MEDICINEApril 2020August 2024Allow5261YesNo
16811086STEM CELL-DERIVED SERTOLI-LIKE CELL, PREPARATION METHOD THEREFOR, AND USE THEREOFMarch 2020June 2024Allow5141YesNo
16808170METHOD FOR PREPARATION OF RETINAL GANGLION CELLSMarch 2020February 2024Allow4840YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NOBLE, MARCIA STEPHENS.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
4
(66.7%)
Examiner Reversed
2
(33.3%)
Reversal Percentile
49.2%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
84
Allowed After Appeal Filing
15
(17.9%)
Not Allowed After Appeal Filing
69
(82.1%)
Filing Benefit Percentile
21.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NOBLE, MARCIA STEPHENS - Prosecution Strategy Guide

Executive Summary

Examiner NOBLE, MARCIA STEPHENS works in Art Unit 1632 and has examined 944 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner NOBLE, MARCIA STEPHENS's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NOBLE, MARCIA STEPHENS receive 2.25 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NOBLE, MARCIA STEPHENS is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +48.9% benefit to allowance rate for applications examined by NOBLE, MARCIA STEPHENS. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 41.3% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 88.0% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.7% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.